Anti-CD4/CD8 antibody therapy induces Foxo1 transcriptional activity promoting T cell egress from inflamed tissue during type 1 diabetesType 1 diabetes (T1D) is considered to be a T cell driven autoimmune disease, for which clinical treatment of T1D has been unsuccessful creating a need for ...
CD8最常见的存在形式是由一个CD8α和一个CD8β链组成的异二聚体,然而,它也可以是由两个CD8α链组成的同二聚体。CD8α和CD8β链均与免疫球蛋白可变轻链具有显著同源性。每个CD8链的分子量约为34 kDa。当在体内使用时,克隆号53-6.7抗体表现出depleting消...
The 53-6.7 antibody is useful for depleting CD8+ peripheral T lymphocytes. It cross reacts with the alpha- and alpha’-like polypeptides on some thymic and peripheral lymphocytes. C57Bl/6 splenocytes were stained with PerCP-Cy5.5 53-6.7 with relevant isotype control in Red. ...
CD8最常见的存在形式是由一个CD8α和一个CD8β链组成的异二聚体,然而,它也可以是由两个CD8α链组成的同二聚体。CD8α和CD8β链均与免疫球蛋白可变轻链具有显著同源性。每个CD8链的分子量约为34 kDa。当在体内使用时,克隆号53-6.7抗体表现出depleting消耗活性。 二 抗体的应用 Application& 产品信息 产品货号 ...
CD8最常见的存在形式是由一个CD8α和一个CD8β链组成的异二聚体,然而,它也可以是由两个CD8α链组成的同二聚体。CD8α和CD8β链均与免疫球蛋白可变轻链具有显著同源性。每个CD8链的分子量约为34 kDa。当在体内使用时,克隆号2.43抗体表现出depleting活性。 二、产品详情 产品详情 产品货号 BE0061 产品规格 ...
Using anti-NK1.1 and anti-CD8-depleting antibodies, we found that while the partial depletion of NK cells did not affect the therapeutic efficacy of the Triplet LNP, the depletion of CD8+ T cells abolished the therapeutic effect completely, indicating that the therapeutic efficacy of the Triplet...
Figure 2. Tumor control required CD8+ T cell-intrinsic IRF2 expression (A and B) Tumor growth kinetics in WT or Irf2−/− mice that received isotype control or anti-CD8-depleting antibody either (A) one day before (early CD8+ T cell depletion) or (B) 21 days after (late CD8+ ...
CD8-depleting antibodies, we found that while the partial depletion of NK cells did not affect the therapeutic efficacy of the Triplet LNP, the depletion of CD8+T cells abolished the therapeutic effect completely, indicating that the therapeutic efficacy of the Triplet LNP is CD8+T cell-dependent...
CD8最常见的存在形式是由一个CD8α和一个CD8β链组成的异二聚体,然而,它也可以是由两个CD8α链组成的同二聚体。CD8α和CD8β链均与免疫球蛋白可变轻链具有显著同源性。每个CD8链的分子量约为34 kDa。当在体内使用时,克隆号53-6.7抗体表现出depleting消耗活性。 二 抗体的应用 Application& 产品信息 产品货号 ...
T cell populations and/or Tregs outside the tumor environment. There remains a need in the art for a monoclonal antibody therapeutic that triggers the death of intratumoral immunosuppressive Tregs without depleting other key effector T cell populations in the tumor microenvironment or peripheral Tregs...